Arthur Michael Jp, Mann Derek A, Iredale John P
University Medicine, University of Southampton, Southampton, United Kingdom.
J Gastroenterol Hepatol. 1998 Sep;13(S1):S33-S38. doi: 10.1111/jgh.1998.13.s1.33.
Hepatic stellate cells (HSC) play a central role in the pathogenesis of liver fibrosis. Following liver injury, these cells proliferate and are activated to a profibrogenic myofibroblastic phenotype. In addition to increased matrix protein synthesis, there is evidence to indicate that these cells are able to regulate matrix degradation. In the early phases of their cellular activation, HSC release matrix metalloproteinases with the ability to degrade the normal liver matrix. When HSC are fully activated, there is a net down-regulation of matrix degradation mediated by increased synthesis and extracellular release of tissue inhibitors of metalloproteinase (TIMP)-1 and -2. These studies in cell culture have been complemented by in vivo studies of hepatic TIMP-1 and TIMP-2 gene expression. In advanced human liver disease of various aetiologies, there is increased TIMP-1-mRNA and protein and increased TIMP-2-mRNA in fibrotic liver compared with control liver. Temporal studies of progressive rat liver fibrosis caused by bile duct ligation or by carbon tetrachloride, indicate an important role for increased TIMP-1 and TIMP-2 expression in pathogenesis. Moreover, in a rat model of reversible liver fibrosis, matrix remodelling and resolution of liver fibrosis is closely associated, temporally, with a marked decrease in TIMP-1 and TIMP-2 expression. These combined cell culture and in vivo findings have led us to investigate the mechanisms of regulation of TIMP-1 gene expression in hepatic stellate cells. Our recent data indicate that transcriptional regulation of TIMP-1 gene expression in HSC is mediated via a mechanism which differs considerably from that previously identified in skin fibroblasts. We conclude that increased TIMP-1 and TIMP-2 expression by HSC plays an important role in the pathogenesis of liver fibrosis. This may represent an important therapeutic target in the design of anti-fibrotic strategies for chronic liver disease.
肝星状细胞(HSC)在肝纤维化的发病机制中起核心作用。肝损伤后,这些细胞增殖并被激活为促纤维化的肌成纤维细胞表型。除了基质蛋白合成增加外,有证据表明这些细胞能够调节基质降解。在其细胞激活的早期阶段,肝星状细胞释放具有降解正常肝基质能力的基质金属蛋白酶。当肝星状细胞完全激活时,基质降解出现净下调,这是由金属蛋白酶组织抑制剂(TIMP)-1和-2的合成增加及细胞外释放介导的。细胞培养中的这些研究得到了肝TIMP-1和TIMP-2基因表达的体内研究的补充。在各种病因的晚期人类肝病中,与对照肝相比,纤维化肝中的TIMP-1-mRNA和蛋白增加,TIMP-2-mRNA也增加。对胆管结扎或四氯化碳引起的进行性大鼠肝纤维化的时间研究表明,TIMP-1和TIMP-2表达增加在发病机制中起重要作用。此外,在可逆性肝纤维化的大鼠模型中,基质重塑和肝纤维化的消退在时间上与TIMP-1和TIMP-2表达的显著降低密切相关。这些细胞培养和体内研究结果相结合,促使我们研究肝星状细胞中TIMP-1基因表达的调控机制。我们最近的数据表明,肝星状细胞中TIMP-1基因表达的转录调控是通过一种与先前在皮肤成纤维细胞中鉴定的机制有很大不同的机制介导的。我们得出结论,肝星状细胞中TIMP-1和TIMP-2表达增加在肝纤维化的发病机制中起重要作用。这可能代表了慢性肝病抗纤维化策略设计中的一个重要治疗靶点。